Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on March 30, 2017. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
The material change reported is the appointment of Dr. Eric J. Ende to the Board of Directors, effective April 3, 2017. Dr. Ende will serve until the next annual shareholder meeting or until a successor is elected. He will also serve on the Audit Committee and Compensation Committee.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. Regarding compensatory arrangements, Dr. Ende will participate in the standard non-employee director compensation plan, which includes:
- An initial option grant to purchase 150,000 shares of common stock.
- An annual retainer fee of $35,000, payable in restricted stock.
Investor Verification Checklist
- Verify the effective date of Dr. Ende's board appointment (April 3, 2017).
- Confirm the specific committee assignments (Audit and Compensation).
- Review the terms of the 150,000 share option grant and the $35,000 restricted stock retainer.
- Check for any potential conflicts of interest given Dr. Ende's prior roles with Icahn Enterprises and other biotech firms.